Merck & Co.
AWARDS
NEWS
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
The drug is being developed and commercialized jointly by AstraZeneca and Merck. It has already been approved for multiple indications in advanced ovarian cancer and metastatic breast cancer.
It’s nice to be admired. Fortune released its list of the most respected companies across the globe and one pharma company made the top 50 list.
Seven pharma executives will enter the Congressional crucible next week as they face questions and concerns over the rising costs of prescription drugs.
Shares of Immune Design are skyrocketing in premarket trading today after Merck announced it will acquire the Seattle-based oncology company for $300 million in cash. Immune Design stock has shot up more than 310 percent to $5.83 in early trading.
Keytruda failed to show a statistical significance in overall survival and progression free survival in the Phase III trial.
JOBS
IN THE PRESS